Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
Curr Opin Biotechnol
2004
15
6
506-12
Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.
Vaccine
2004
23
2
215-21
Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.
J Gen Virol
2004
85
Pt 10
2915-24
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway.
Cancer Res
2004
64
1
215-20
Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man.
Int J Cancer
2004
108
4
571-9
Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.
J Gen Virol
2004
85
Pt 8
2407-19
Autologous cytotoxicity of natural killer cells derived from HIV-infected patients.
Immunol Lett
2004
91
2-3
155-8
Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.
Clin Diagn Lab Immunol
2004
11
2
406-10
Molecular aspects of disease pathogenesis in the transmissible spongiform encephalopathies.
Methods Mol Biol
2004
268
517-40